Fault Lines and Pressure Points: Building Geopolitical Resilience Within Life Sciences Organizations
Geopolitical disruption has become a standing risk for drugmakers. It calls for a standing response: a resilient, adaptable operating model built to withstand these fault lines and pressure points.
Salesforce Wants an Agentic Future. But What Will It Cost?
Salesforce customers already pay to store and manage their data on the platform. But as Salesforce continues its push toward an agentic future, they may pay again every time an AI agent accesses it.
Complex organizations tend to have complex product catalogs. As those catalogs expand and evolve, pricing models become more nuanced, configurations more interdependent, and more stakeholders become involved in how deals are structured and approved. Quoting complexity follows naturally. Managing that complexity — and finding tools capable of supporting it — becomes its own challenge. This is the environment Salesforce Revenue Cloud Advanced was designed to support.
AI can accelerate life sciences, but only if operating models evolve with it. Five dimensions define whether AI is embedded structurally or stays a pilot.
Coupa Inspire 2026: The Next Phase of Spend Management Takes Shape
Coupa Inspire 2026 marked Coupa's 20th anniversary, and the conference reflected a company positioning itself for a new phase of growth. Coupa is building its roadmap around AI-enabled workflows, automation, and orchestration across the full spend lifecycle.
If You’re Looking for Transformation Funding, Start with Procurement Savings
Procurement, when managed strategically, can surface potential millions in unrealized savings that can be deployed to fund your next transformation initiative.
Explore expert insights and practical perspectives from the Acquis team on the trends and topics shaping today’s business landscape
Capability
Industry
Topic
Article
Employers Are Asking the Wrong Question About Benefits Utilization
Acquis partnered with Cara Collective for its recent IRL to answer the question benefits leaders have asked for years: why do frontline workers let employer benefits go unused?
Senior leaders have moved quickly to put AI into their workforces. Now, they face the harder work of deciding what AI should change and how to prove its value.
Fault Lines and Pressure Points: Building Geopolitical Resilience Within Life Sciences Organizations
Geopolitical disruption has become a standing risk for drugmakers. It calls for a standing response: a resilient, adaptable operating model built to withstand these fault lines and pressure points.
Salesforce Wants an Agentic Future. But What Will It Cost?
Salesforce customers already pay to store and manage their data on the platform. But as Salesforce continues its push toward an agentic future, they may pay again every time an AI agent accesses it.
Dreamforce 2026 introduced a series of major announcements spanning AI models, purpose-built agents, new interfaces, and expanded partnerships. Taken together, they demonstrate Salesforce’s rapid migration from its traditional application interface toward an agentic enterprise that sits underneath the work, wherever that work happens.
Combination Multiplication: A Compounding Return for Oncology
Combinations are not new. What is new is the velocity. The number of regimens pairing established immuno-oncology (IO) agents with novel molecules and mechanisms has grown significantly year over year, and the data supporting those pairings is maturing in ways that carry real implications for patients, drugmakers, and the broader life sciences investment thesis.
Coupa Inspire 2026: The Next Phase of Spend Management Takes Shape
Coupa Inspire 2026 marked Coupa's 20th anniversary, and the conference reflected a company positioning itself for a new phase of growth. Coupa is building its roadmap around AI-enabled workflows, automation, and orchestration across the full spend lifecycle.
The May 2025 Most Favored Nation (MFN) executive order aims to align US drug pricing with the lowest prices paid by other developed nations. On the surface, it is a pricing policy. In practice, it is something more consequential.